STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #591 by analyst upside · 2026-06-27
TENX
Tenax Therapeutics, Inc.
Healthcare · Market Cap $356M · P/E 0x
ANALYST PRICE TARGET
+152.0%
implied upside to consensus target
Current Price $13.44
Consensus Target $33.88
Bull Target $50.0
Bear Target $26.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
0
Sell
0
52-Week Low $5.66
52-Week High $18.38
YTD Return +21.6%
FUNDAMENTALS
Market Cap $356M
P/E Ratio (TTM) N/A
Forward P/E -9.7x
EPS (TTM) $-1.47
PEG Ratio 1.44
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $5.66
52-Week High $18.38
Current Price $13.44
Bear Target $26.0
Bull Target $50.0
● Now $13.44 ● Target $33.88
TRADING DATA
Avg Volume 711K
YTD Return +21.6%
Analyst Count 8
Consensus Buy
Upside to Target +152.0%
Last Updated 2026-06-27

ANALYST SUMMARY

Tenax Therapeutics, Inc. (TENX) is currently trading at $13.44 with a Wall Street consensus price target of $33.88, implying potential upside of 152.0% over the next 12 months. 8 analysts currently cover TENX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $50.0, while the most cautious has a target of $26.0.

TENX operates in the Healthcare sector with a market capitalisation of $356M. The stock is up 21.6% year-to-date and is currently trading near the upper end of its 52-week range of $5.66 – $18.38.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for TENX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Piper Sandler — Reiterated
Overweight → Overweight 2026-06-12 14% win rate (7 calls)
Cantor Fitzgerald ● Initiated
Overweight 2026-03-17 40% win rate (10 calls)
Guggenheim — Reiterated
Buy → Buy 2026-03-16 62% win rate (8 calls)
Guggenheim — Reiterated
Buy → Buy 2025-12-17 62% win rate (8 calls)
Piper Sandler ● Initiated
Overweight 2025-09-08 14% win rate (7 calls)
Guggenheim — Reiterated
Buy → Buy 2025-08-14 62% win rate (8 calls)
Leerink Partners ● Initiated
Outperform 2024-10-24 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →